Pfizer Early Stage GT
The study will evaluate the safety and dystrophin expression following gene therapy in boys with Duchenne Muscular Dystrophy (DMD). It is a single-arm, non-randomized, open-label study
- Investigator
- Barry J Byrne
- Status
- Accepting Candidates
- Ages
- 2 Years - 3 Years
- Sexes
- Male
ATB200-08
This is a Phase 3, open-label, multicenter study to evaluate the safety, efficacy, PK, PD, and immunogenicity of cipaglucosidase alfa/miglustat treatment in ERT-experienced and ERT-naïve pediatric subjects with IOPD.
- Investigator
- Barry J Byrne
- Status
- Accepting Candidates
- Ages
- N/A - 17 Years
- Sexes
- All
TECPR2 Obs
The purpose of this study is to learn more about the disease progression in patients with a TECPR2 mutation.
- Investigator
- Barry J Byrne
- Status
- Accepting Candidates
- Ages
- 18 Months - 12 Years
- Sexes
- All